

Nicola Squillace

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6036495/publications.pdf>

Version: 2024-02-01

78
papers

1,562
citations

361296

20
h-index

345118

36
g-index

82
all docs

82
docs citations

82
times ranked

2741
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Nonalcoholic Fatty Liver Disease in HIV-Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors. <i>Clinical Infectious Diseases</i> , 2008, 47, 250-257. | 2.9 | 208 |
| 2 | Cardiovascular risk and dyslipidemia among persons living with HIV: a review. <i>BMC Infectious Diseases</i> , 2017, 17, 551. | 1.3 | 112 |
| 3 | Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCOVID-19 prospective trial. <i>Journal of Translational Medicine</i> , 2020, 18, 405. | 1.8 | 98 |
| 4 | The NLRP3 Inflammasome Is Upregulated in HIV-Infected Antiretroviral Therapy-Treated Individuals with Defective Immune Recovery. <i>Frontiers in Immunology</i> , 2018, 9, 214. | 2.2 | 71 |
| 5 | Weight Gain: A Possible Side Effect of All Antiretrovirals. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx239. | 0.4 | 68 |
| 6 | Sexual Dysfunction in HIV-Infected Men: Role of Antiretroviral Therapy, Hypogonadism and Lipodystrophy. <i>Antiviral Therapy</i> , 2007, 12, 1059-1066. | 0.6 | 54 |
| 7 | Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir. <i>Aids</i> , 2017, 31, 455-457. | 1.0 | 47 |
| 8 | Factors Associated With Weight Gain in People Treated With Dolutegravir. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa195. | 0.4 | 47 |
| 9 | Multidisciplinary Approach to the Treatment of Metabolic and Morphologic Alterations of HIV-Related Lipodystrophy. <i>HIV Clinical Trials</i> , 2006, 7, 97-106. | 2.0 | 45 |
| 10 | Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). <i>BMC Infectious Diseases</i> , 2018, 18, 357. | 1.3 | 42 |
| 11 | Severity of Lipodystrophy Is Associated with Decreased Health-Related Quality of Life. <i>AIDS Patient Care and STDs</i> , 2008, 22, 577-585. | 1.1 | 41 |
| 12 | Tularaemia outbreak in Bulgaria. <i>Scandinavian Journal of Infectious Diseases</i> , 2004, 36, 785-789. | 1.5 | 36 |
| 13 | Body image is a major determinant of sexual dysfunction in stable HIV-infected women. <i>Antiviral Therapy</i> , 2009, 14, 85-92. | 0.6 | 35 |
| 14 | Lipodystrophy and quality of life of HIV-infected persons. <i>AIDS Reviews</i> , 2008, 10, 152-61. | 0.5 | 31 |
| 15 | Clusterization of co-morbidities and multi-morbidities among persons living with HIV: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2019, 19, 555. | 1.3 | 29 |
| 16 | Detectable HIV Viral Load Is Associated With Metabolic Syndrome. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 459-464. | 0.9 | 27 |
| 17 | Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3067-3075. | 1.3 | 26 |
| 18 | Factors associated with hospital admission for COVID-19 in HIV patients. <i>Aids</i> , 2020, 34, 1983-1985. | 1.0 | 26 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Long-Term Psychometric Outcomes of Facial Lipoatrophy Therapy: Forty-Eight-Week Observational, Nonrandomized Study. <i>AIDS Patient Care and STDs</i> , 2007, 21, 833-842. | 1.1 | 25 |
| 20 | <p>The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 5515-5520. | 2.0 | 24 |
| 21 | <p>Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project</p>. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 1385-1391. | 1.1 | 19 |
| 22 | Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. <i>PLoS ONE</i> , 2017, 12, e0179254. | 1.1 | 17 |
| 23 | Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 615-623. | 1.1 | 17 |
| 24 | A Case of Cerebrospinal Fluid Viral Escape on a Dual Antiretroviral Regimen: Worth the Risk?. <i>Clinical Infectious Diseases</i> , 2014, 59, 1655-1656. | 2.9 | 16 |
| 25 | Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated With the Evolution of Cognitive Performance in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 219-224. | 0.9 | 16 |
| 26 | Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection"Results of Italian Network of ACuTe HIV InfectiON (INACTiON) Retrospective Study. <i>Pathogens and Immunity</i> , 2020, 5, 8. | 1.4 | 16 |
| 27 | Glomerular filtration rates in HIV-infected patients treated with and without tenofovir: a prospective, observational study. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 63, 374-379. | 1.3 | 15 |
| 28 | miRNA-218 Targets Lipin-1 and Glucose Transporter Type 4 Genes in 3T3-L1 Cells Treated With Lopinavir/Ritonavir. <i>Frontiers in Pharmacology</i> , 2019, 10, 461. | 1.6 | 15 |
| 29 | Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 119-127. | 0.9 | 15 |
| 30 | Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study. <i>AIDS Patient Care and STDs</i> , 2021, 35, 342-353. | 1.1 | 15 |
| 31 | Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study. <i>BMC Public Health</i> , 2020, 20, 734. | 1.2 | 15 |
| 32 | Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and lipodystrophy. <i>Antiviral Therapy</i> , 2007, 12, 1059-65. | 0.6 | 15 |
| 33 | Prevalence of and Risk Factors for Pubic Lipoma Development in HIV-Infected Persons. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, 72-76. | 0.9 | 14 |
| 34 | Cardiovascular Events Recurrence and Coronary Artery Disease in HIV Patients: The Price We Have to Pay for the Chronicization of the Disease. <i>Canadian Journal of Cardiology</i> , 2020, 36, 127-134. | 0.8 | 14 |
| 35 | Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances. <i>Aids</i> , 2020, 34, 53-61. | 1.0 | 14 |
| 36 | Brachial and central blood pressure in HIV-infected subjects. <i>Hypertension Research</i> , 2015, 38, 405-412. | 1.5 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: review of the literature and suggestions for a friendly use. <i>AIDS Research and Therapy</i> , 2019, 16, 11. | 0.7 | 13 |
| 38 | Hyperhomocysteinaemia in HIV-infected patients: determinants of variability and correlations with predictors of cardiovascular disease. <i>HIV Medicine</i> , 2009, 10, 28-34. | 1.0 | 12 |
| 39 | Unmasking tuberculosis in the era of antiretroviral treatment. <i>European Respiratory Journal</i> , 2012, 39, 1064-1075. | 3.1 | 12 |
| 40 | Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 3635-3643. | 2.0 | 12 |
| 41 | Nonalcoholic fatty liver disease and steatohepatitis in people living with HIV. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 643-650. | 1.4 | 11 |
| 42 | Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade. <i>HIV Medicine</i> , 2022, 23, 70-79. | 1.0 | 11 |
| 43 | Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2663-2669. | 1.3 | 10 |
| 44 | Reversibility of Central Nervous System Adverse Events in Course of Art. <i>Viruses</i> , 2022, 14, 1028. | 1.5 | 8 |
| 45 | Metabolic disorders induced by highly active antiretroviral therapy and their relationship with vascular remodeling of the brachial artery in a population of HIV-infected patients. <i>Metabolism: Clinical and Experimental</i> , 2009, 58, 927-933. | 1.5 | 7 |
| 46 | The Role of the Framingham Risk Score to Predict the Presence of Subclinical Coronary Atherosclerosis in Patients with HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 303-304. | 0.9 | 7 |
| 47 | Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2017, 41, e76-e79. | 0.7 | 7 |
| 48 | HIV and SARS-CoV-2 Co-Infection: What are the Risks?. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 3991-4014. | 1.1 | 7 |
| 49 | Nonalcoholic Fatty Liver Disease in HIV-Infected Persons: Epidemiology and the Role of Nucleoside Reverse Transcriptase Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 278. | 0.9 | 6 |
| 50 | Prospective Immune Dynamics during the First 24 Weeks of Efavirenz Based-Antiretroviral Therapy in HIV-1-Infected Subjects, According to CD4+ T-Cell Counts at Presentation: The IMMUNEF Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0117118. | 1.1 | 6 |
| 51 | Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2162-2170. | 1.3 | 6 |
| 52 | Smoking Habits in Human Immunodeficiency Virus-Infected People from Italy: A Cross-Sectional Analysis of the STOPSHIV Cohort. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 19-26. | 0.5 | 6 |
| 53 | <p>Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort</p>. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 2291-2300. | 1.1 | 6 |
| 54 | Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort. <i>HIV Medicine</i> , 2020, 21, 523-535. | 1.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Invasive pulmonary and cerebral aspergillosis in a patient with Weil's disease. <i>Scandinavian Journal of Infectious Diseases</i> , 2005, 37, 396-398. | 1.5 | 5 |
| 56 | Safety of darunavir/ritonavir (DRV/r) in HIV-1-infected DRV/r-experienced and -naïve patients: analysis of data in the real-world setting in Italy. <i>Journal of the International AIDS Society</i> , 2014, 17, 19573. | 1.2 | 5 |
| 57 | Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA). <i>AIDS Research and Therapy</i> , 2019, 16, 21. | 0.7 | 5 |
| 58 | Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression. <i>Patient</i> , 2020, 13, 375-387. | 1.1 | 5 |
| 59 | Focal bone lesions in hiv-positive patient treated with tenofovir. <i>BMC Infectious Diseases</i> , 2014, 14, 131. | 1.3 | 4 |
| 60 | Is It Feasible to Impact on Smoking Habits in HIV-Infected Patients? Mission Impossible From the STOPSHIV Project Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 496-503. | 0.9 | 4 |
| 61 | Use of statins and aspirin to prevent cardiovascular disease among HIV-positive patients. A survey among Italian HIV physicians. <i>New Microbiologica</i> , 2017, 40, 139-142. | 0.1 | 4 |
| 62 | Hepatitis C virus antibody-positive patients with HIV infection have a high risk of insulin resistance: a cross-sectional study. <i>HIV Medicine</i> , 2008, 9, 151-159. | 1.0 | 3 |
| 63 | Heterologous Fat Transplantation for the Treatment of HIV-Related Facial Lipoatrophy. <i>Annals of Internal Medicine</i> , 2009, 150, 61. | 2.0 | 3 |
| 64 | Ultrasonographic backscatter of the carotid artery wall in patients with HIV infection: A pilot study. <i>Blood Pressure</i> , 2010, 19, 344-350. | 0.7 | 3 |
| 65 | Similar Success Rates but Lower Incidence of Telaprevir-Related Rash in HIV/HCV Coinfected as Compared to HCV-Monoinfected Patients Treated With Triple Anti-HCV Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, e37-e40. | 0.9 | 3 |
| 66 | HPV 16 and 18 contribute to development of anal dysplasia in HIV infection irrespective of gender and sexual orientation. <i>HIV Medicine</i> , 2021, 22, 860-866. | 1.0 | 3 |
| 67 | High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects. <i>Medicine (United States)</i> , 2016, 95, e4434. | 0.4 | 2 |
| 68 | Higher Levels of Peripheral Th17 T CD4+ Cells Are Associated With Immunological Non Response in HIV-Infected Patients Under Effective ART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, e45-e47. | 0.9 | 2 |
| 69 | Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: relapse or late IRIS?. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1190-1191. | 1.3 | 1 |
| 70 | Therapy of Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: Is There an Optimal Interleukin 6 Cutoff for Successful Tocilizumab Treatment?. <i>Clinical Infectious Diseases</i> , 2020, 73, e270-e271. | 2.9 | 1 |
| 71 | miRNA Expression Profiling in Subcutaneous Adipose Tissue of Monozygotic Twins Discordant for HIV Infection: Validation of Differentially Expressed miRNA and Bioinformatic Analysis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3486. | 1.8 | 1 |
| 72 | Reply to Remtulla and Decker. <i>Clinical Infectious Diseases</i> , 2008, 47, 1234-1234. | 2.9 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Immunological failure in an HIV Ælite controller: possible role of indirect markers of inflammation and benefit of antiretroviral therapy. <i>Aids</i> , 2020, 34, 646-647. | 1.0 | 0 |
| 74 | The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 1389-1392. | 1.1 | 0 |
| 75 | La steatosi epatica non alcolica in HIV: una revisione critica della letteratura.. <i>JHA - Journal of HIV and Ageing</i> , 2018, , . | 0.0 | 0 |
| 76 | Clusterizzazione di comorbiditÃ e multimorbiditÃ tra le persone che vivono con HIV, e rischio di interazione malattia-malattia: report preliminare. <i>JHA - Journal of HIV and Ageing</i> , 2018, , . | 0.0 | 0 |
| 77 | Switch da Tenofovir disoproxil fumarato (TDF) a Tenofovir alafenamide (TAF) e aumento del colesterolo: impatto sulla valutazione del rischio cardiovascolare.. <i>JHA - Journal of HIV and Ageing</i> , 2019, , . | 0.0 | 0 |
| 78 | SLAM Project - Second-Level Diagnostic Assessment: Multidisciplinary approach to HIV Patients. <i>New Microbiologica</i> , 2019, 42, 150-155. | 0.1 | 0 |